Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group. They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment. The clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients
Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation
You may qualify if…
- ✓ male and female patients aged 18 to 75 years
- ✓ diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria
- ✓ for episodic migraine: 8-14 monthly migraine days in the previous 3 months
- ✓ diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months
- ✓ patients naive to CGRP targeting treatments
You may not qualify if…
- ✕ history of major psychiatric or other neurological conditions
- ✕ diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)
- ✕ clinically significant medical conditions
- ✕ chronic pain conditions
- ✕ alcohol and/or drug abuse
- ✕ pregnancy or lactation
Source: ClinicalTrials.gov · NCT06562400 · last updated 2024-08-20